Matthew Patterson
2017
In 2017, Matthew Patterson earned a total compensation of $6.9M as President, Chief Executive Officer and Director at Audentes Therapeutics, a 968% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $239,890 |
|---|---|
| Option Awards | $6,207,510 |
| Salary | $479,780 |
| Total | $6,927,180 |
Patterson received $6.2M in option awards, accounting for 90% of the total pay in 2017.
Patterson also received $239.9K in non-equity incentive plan and $479.8K in salary.
Rankings
In 2017, Matthew Patterson's compensation ranked 1,187th out of 14,666 executives tracked by ExecPay. In other words, Patterson earned more than 91.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,187 out of 14,666 | 92nd |
Division Manufacturing | 399 out of 5,772 | 93rd |
Major group Chemicals And Allied Products | 106 out of 2,075 | 95th |
Industry group Drugs | 73 out of 1,731 | 96th |
Industry Biological Products, Except Diagnostic Substances | 14 out of 313 | 96th |
Source: SEC filing on April 27, 2018.
Patterson's colleagues
We found three more compensation records of executives who worked with Matthew Patterson at Audentes Therapeutics in 2017.